Cepheid (CPHD +5.2%) ramps higher after reporting preliminary Q4 results, saying its EPS should come in just above its prior guidance of $0.10 to $0.12 a share due to a favorable revenue mix. Analysts have been expecting a $0.02 per share net loss for the quarter. Revenue is expected to be below its prior view however, driven by weaker clinical revenue from high-burden developing countries
Market Data 
Markets 
AI
